CASTELLUM, INC., 10-Q filed on 11/7/2025
Quarterly Report
v3.25.3
Cover Page - shares
9 Months Ended
Sep. 30, 2025
Nov. 06, 2025
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2025  
Document Transition Report false  
Entity File Number 001-41526  
Entity Registrant Name CASTELLUM, INC.  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 27-4079982  
Entity Address, Address Line One 1934 Old Gallows Road  
Entity Address, Address Line Two Suite 350  
Entity Address, City or Town Vienna  
Entity Address, State or Province VA  
Entity Address, Postal Zip Code 22182  
City Area Code 703  
Local Phone Number 752-6157  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol CTM  
Security Exchange Name NYSEAMER  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   94,612,750
Entity Central Index Key 0001877939  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.25.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Current Assets:    
Cash $ 17,818,338 $ 12,005,048
Restricted Cash 0 250,000
Accounts receivable, net 9,369,829 5,507,384
Contract asset 431,003 270,147
Due from buyer 133,588 36,214
Prepaid income taxes 152,444 154,793
Prepaid expenses and other current assets 744,037 667,592
Total current assets 28,649,239 18,891,178
Fixed assets, net 240,143 156,111
Non-Current Assets:    
Due from buyer, net of current portion 26,633 191,470
Right of use asset - operating lease 880,278 1,075,982
Investment in captive insurance entity 0 52,110
Other long term receivable 52,360 0
Intangible assets, net 5,727,136 6,793,750
Goodwill 10,676,834 10,676,834
Total non-current assets 17,603,384 18,946,257
Total Assets 46,252,623 37,837,435
Current Liabilities    
Accounts payable and accrued expenses 2,375,109 1,140,321
Accrued payroll and payroll related expenses 3,340,625 3,398,300
Current portion of lease liability – operating leases 290,199 310,380
Due to seller 160,000 240,000
Obligation to issue common and preferred stock 0 402,708
Derivative liability 348,000 883,000
Revolving credit facility 0 1,999,944
Total current liabilities 6,863,933 9,824,653
Non-Current Liabilities    
Lease liability – operating leases, net of current portion 609,878 780,756
Due to seller, net of current portion 0 100,000
Note payable – related party, net of current portion 50,000 150,000
Total non-current liabilities 2,659,878 7,830,756
Total Liabilities 9,523,811 17,655,409
Stockholders' Equity    
Common stock, par value, $0.0001, 3,000,000,000 shares authorized, 94,612,750 and 77,076,129 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 9,461 7,707
Additional paid in capital 91,958,566 74,256,138
Accumulated deficit (55,239,860) (54,082,484)
Total stockholders' equity 36,728,812 20,182,026
Total Liabilities and Stockholders' Equity 46,252,623 37,837,435
Related party    
Current Liabilities    
Notes payable, current 350,000 250,000
Nonrelated Party    
Current Liabilities    
Notes payable, current 0 1,200,000
Non-Current Liabilities    
Notes payable, noncurrent 2,000,000 6,800,000
Series A Preferred    
Stockholders' Equity    
Preferred stock, value, issued 588 588
Series C Preferred    
Stockholders' Equity    
Preferred stock, value, issued $ 57 $ 77
v3.25.3
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares
Sep. 30, 2025
Dec. 31, 2024
Preferred stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 3,000,000,000 3,000,000,000
Common stock, shares, issued (in shares) 94,612,750 77,076,129
Common stock, shares outstanding (in shares) 94,612,750 77,076,129
Series A Preferred    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock par or stated value per share (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, shares issued (in shares) 5,875,000 5,875,000
Preferred stock, shares outstanding (in shares) 5,875,000 5,875,000
Series C Preferred    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock par or stated value per share (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, shares issued (in shares) 570,000 770,000
Preferred stock, shares outstanding (in shares) 570,000 770,000
v3.25.3
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]        
Revenues $ 14,619,687 $ 11,608,691 $ 40,308,142 $ 34,466,131
Cost of Revenues 9,129,119 6,650,035 25,202,512 20,318,846
Gross Profit 5,490,568 4,958,656 15,105,630 14,147,285
Operating Expenses        
Indirect costs 2,195,712 2,449,974 6,797,986 7,152,304
Overhead 473,496 495,482 1,483,727 1,464,363
General and administrative 2,376,080 3,396,297 8,248,167 11,155,142
Total operating expenses 5,045,288 6,341,753 16,529,880 19,771,809
Income (Loss) From Operations Before Other Income (Expense) 445,280 (1,383,097) (1,424,250) (5,624,524)
Other Income (Expense)        
Loss on extinguishment of debt 0 0 0 (822,847)
Gain from change in fair value of derivative liability 18,000 15,000 535,000 117,400
Gain on sale of subsidiary 0 39,234 0 39,234
Interest expense, net of interest income 58,838 (208,709) (82,283) (950,905)
Total other income (expense) 76,838 (154,475) 452,717 (1,617,118)
Income (Loss) Before Income Taxes and Preferred Stock Dividends 522,118 (1,537,572) (971,533) (7,241,642)
Income tax benefit (expense) (106,717) 257,480 (105,220) 3,090
Net Income (Loss) 415,401 (1,280,092) (1,076,753) (7,238,552)
Less: preferred stock dividends 26,819 29,819 80,623 89,458
Net Income (Loss) To Common Shareholders $ 388,582 $ (1,309,911) $ (1,157,376) $ (7,328,010)
Net Income (Loss) Per Share - Basic And Diluted        
Net loss per share, basic (in usd per share) $ 0.00 $ (0.02) $ (0.01) $ (0.13)
Net loss per share, diluted (in usd per share) $ 0.00 $ (0.02) $ (0.01) $ (0.13)
Weighted average shares outstanding, basic (in shares) 89,765,186 57,190,645 87,053,046 54,845,606
Weighted average shares outstanding, diluted (in shares) 89,765,186 57,190,645 87,053,046 54,845,606
v3.25.3
Consolidated Statement Of Changes In Stockholders' Equity (Unaudited) - USD ($)
Total
Revision of Prior Period, Error Correction, Adjustment
Private Warrant
Pre-Funded Warrants
Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Revision of Prior Period, Error Correction, Adjustment
Additional Paid-In Capital
Private Warrant
Additional Paid-In Capital
Pre-Funded Warrants
Accumulated Deficit
Series A Preferred
Preferred Stock
Series B Preferred
Preferred Stock
Series C Preferred
Preferred Stock
Beginning balance (in shares) at Dec. 31, 2023         47,672,427           5,875,000 0 770,000
Beginning balance at Dec. 31, 2023 $ 12,948,689       $ 4,767 $ 56,926,161       $ (43,982,904) $ 588 $ 0 $ 77
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 1,657,822         1,657,822              
Stock issued during period, shares, new issues (in shares)         5,357,487                
Shares issued to institutional investor 755,767       $ 536 755,231              
Warrants issues (in shares)     $ 1,081,471 $ 525,905       $ 1,081,471 $ 525,905        
Net income (loss) for the period (4,141,541)                 (4,141,541)      
Ending balance (in shares) at Mar. 31, 2024         53,029,914           5,875,000 0 770,000
Ending balance at Mar. 31, 2024 12,828,113       $ 5,303 60,946,590       (48,124,445) $ 588 $ 0 $ 77
Beginning balance (in shares) at Dec. 31, 2023         47,672,427           5,875,000 0 770,000
Beginning balance at Dec. 31, 2023 12,948,689       $ 4,767 56,926,161       (43,982,904) $ 588 $ 0 $ 77
Ending balance (in shares) at Dec. 31, 2024         77,076,129           5,875,000 0 770,000
Ending balance at Dec. 31, 2024 20,182,026       $ 7,707 74,256,138       (54,082,484) $ 588 $ 0 $ 77
Beginning balance (in shares) at Mar. 31, 2024         53,029,914           5,875,000 0 770,000
Beginning balance at Mar. 31, 2024 12,828,113       $ 5,303 60,946,590       (48,124,445) $ 588 $ 0 $ 77
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 1,127,762         1,127,762              
Net income (loss) for the period (1,876,554)                 (1,876,554)      
Ending balance (in shares) at Jun. 30, 2024         53,029,914           5,875,000 0 770,000
Ending balance at Jun. 30, 2024 12,079,321       $ 5,303 62,074,352       (50,000,999) $ 588 $ 0 $ 77
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 1,252,574         1,252,574              
Stock issued during period, shares, new issues (in shares)         3,080,014                
Shares issued to institutional investor 3,080       $ 308 2,772              
Net income (loss) for the period (1,309,911)                 (1,309,911)      
Ending balance (in shares) at Sep. 30, 2024         56,109,928           5,875,000 0 770,000
Ending balance at Sep. 30, 2024 12,025,064       $ 5,611 63,329,698       (51,310,910) $ 588 $ 0 $ 77
Beginning balance (in shares) at Dec. 31, 2024         77,076,129           5,875,000 0 770,000
Beginning balance at Dec. 31, 2024 20,182,026       $ 7,707 74,256,138       (54,082,484) $ 588 $ 0 $ 77
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 1,179,207         1,179,207              
Shares issued in exercise of stock options (in shares)         110,028                
Stock options exercised 0       $ 11 (11)              
Sale of common stock, net of filing fees (in shares)         4,500,000                
Sale of common stock, net of filing fees 3,995,928       $ 450 3,995,478              
Warrants exercised (in shares)         4,225,717                
Warrants exercised 1,936,601       $ 423 1,936,178              
Preferred stock conversion to common stock (in shares)         125,000               (200,000)
Preferred stock conversion to common stock 1       $ 13 8             $ (20)
Net income (loss) for the period (1,197,031)                 (1,197,031)      
Ending balance (in shares) at Mar. 31, 2025         86,036,874           5,875,000 0 570,000
Ending balance at Mar. 31, 2025 26,096,732       $ 8,604 81,366,998       (55,279,515) $ 588 $ 0 $ 57
Beginning balance (in shares) at Dec. 31, 2024         77,076,129           5,875,000 0 770,000
Beginning balance at Dec. 31, 2024 $ 20,182,026       $ 7,707 74,256,138       (54,082,484) $ 588 $ 0 $ 77
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock issued during period, shares, new issues (in shares)         17,536,621                
Shares issued in exercise of stock options (in shares) 250,000                        
Ending balance (in shares) at Sep. 30, 2025         94,612,750           5,875,000 0 570,000
Ending balance at Sep. 30, 2025 $ 36,728,812       $ 9,461 91,958,566 $ 274,500     (55,239,860) $ 588 $ 0 $ 57
Beginning balance (in shares) at Mar. 31, 2025         86,036,874           5,875,000 0 570,000
Beginning balance at Mar. 31, 2025 26,096,732       $ 8,604 81,366,998       (55,279,515) $ 588 $ 0 $ 57
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 640,021         640,021              
Sale of common stock, net of filing fees (in shares)         4,166,667                
Sale of common stock, net of filing fees 4,470,406       $ 416 4,469,990              
Warrants exercised (in shares)         610,543                
Warrants exercised 639,770       $ 61 639,709              
Balance sheet reclassification adjustment   $ 274,500         274,500            
Net income (loss) for the period (348,927)                 (348,927)      
Ending balance (in shares) at Jun. 30, 2025         90,814,084           5,875,000 0 570,000
Ending balance at Jun. 30, 2025 31,772,502       $ 9,081 87,391,218       (55,628,442) $ 588 $ 0 $ 57
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Stock-based compensation - options 284,116         284,116              
Shares issued in exercise of stock options (in shares)         125,000                
Stock options exercised 26,501       $ 13 26,488              
Warrants exercised (in shares)         3,673,666                
Warrants exercised 4,257,111       $ 367 4,256,744              
Net income (loss) for the period 388,582                 388,582      
Ending balance (in shares) at Sep. 30, 2025         94,612,750           5,875,000 0 570,000
Ending balance at Sep. 30, 2025 $ 36,728,812       $ 9,461 $ 91,958,566 $ 274,500     $ (55,239,860) $ 588 $ 0 $ 57
v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash Flow From Operating Activities    
Net loss before preferred stock dividends $ (1,076,753) $ (7,238,552)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 1,124,503 1,723,553
Amortization of discounts, premium and deferred costs 0 1,118,194
Stock-based compensation 2,103,344 4,184,930
Deferred tax provision 0 (6,290)
Lease cost 195,709 214,672
Gain on sale of subsidiary 0 (39,234)
Change in fair value of derivative liability (535,000) (117,400)
Gain on lease termination 0 (9,225)
Changes in assets and liabilities    
Accounts receivable (3,862,444) 932,912
Prepaid expenses and other current assets (61,255) (134,336)
Contract asset (liability) (160,856) 154,865
Accounts payable and accrued expenses 1,177,114 932,076
Lease liability (191,060) (201,628)
Net cash (used in) provided by operating activities (1,286,698) 1,514,537
Cash Flows From Investing Activities    
Sale of subsidiary, cash received from buyer 67,463 109,523
Purchases of fixed assets (141,924) (3,317)
Investment in captive insurance entity/other investment (250) (54,534)
Net cash used in investing activities (74,711) 51,672
Cash Flows From Financing Activities    
Proceeds from revolving credit line 0 889,793
Settlement of stock compensation in cash (128,207) 0
Payment of revolving line of credit (1,999,944) 0
Payment of debt issuance costs (12,844) (19,266)
Proceeds from issuance of common stock, prefunded warrants and regular warrants, net of issuance costs 15,299,817 2,366,223
Preferred stock dividend (80,623) (89,458)
Repayment of amounts due to seller (180,000) (670,000)
Proceeds from exercise of stock options 26,500 0
Net cash provided by (used in) financing activities 6,924,699 (654,089)
Net increase in cash 5,563,290 912,120
Cash - Beginning of Period 12,255,048 1,830,841
Cash - End of Period 17,818,338 2,742,961
Supplemental Disclosures    
Cash paid for interest expense 397,185 607,133
Cash paid from income taxes 102,854 25,813
Summary of Non-Cash Activities:    
Derecognition of lease liability 0 396,388
Derecognition of right of use asset 0 387,164
Related Parties    
Cash Flows From Financing Activities    
Repayments of convertible debt 0 (809,617)
Nonrelated Parties    
Cash Flows From Financing Activities    
Repayment of note payable $ (6,000,000) $ (2,321,764)
v3.25.3
Nature of Operations
9 Months Ended
Sep. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Castellum, Inc. (the “Company”) is focused on building a large, successful technology company in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal civilian, state and local governments, and commercial markets (the "Markets"). Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model based systems engineering ("MBSE"). These services, which largely focus on securing data and establishing related policies, are applicable to customers in the United States ("U.S.") government, financial services, healthcare, and other users of large data applications. The services can be delivered to legacy customer owned networks, or customers who rely upon cloud-based infrastructures.
Since November 2019, the Company has made the following acquisitions that specialize in the areas noted above:
Corvus Consulting, LLC (“Corvus”),
Mainnerve Federal Services, Inc. dba MFSI Government Group (“MFSI"),
Merrison Technologies, LLC ("Merrison"),
Specialty Systems, Inc. (“SSI”),
the business assets of Pax River from The Albers Group (“Pax River”),
Lexington Solutions Group, LLC (“LSG”), and
Global Technology and Management Resources, Inc. ("GTMR").
The Company works with multiple investment bankers and contacts within its business network to identify potential acquisitions.
With the exception of Pax River, all of these acquisitions were considered business combinations under Topic 805 Business Combinations of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). See Note 3, “Disposition” for detail on the disposition of MFSI in 2024.
v3.25.3
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated financial statements, including the notes, include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.
Basis of Presentation for Interim Periods
Certain information and footnote disclosures normally included for the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted for the interim periods presented. We believe that the unaudited interim financial statements include all adjustments (which are normal and recurring in nature) necessary to present fairly our financial position and the results of operations and cash flows for the periods presented.
The results of operations for the interim periods presented are not necessarily indicative of results that may be expected for the year or future periods. The financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K for the year then ended. We have continued to follow the accounting policies set forth in those financial statements.
Business Segments
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM, the Chief Executive Officer, reviews consolidated results of operations to make decisions. The Company maintains one operating and reportable segment, which is the delivery of products and
services in the areas of information technology, electronic warfare, information warfare, and cybersecurity in the governmental and commercial markets.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers ("ASC 606"). The Company accounts for a contract with a customer that is within the scope of this Topic only when the five steps of revenue recognition under ASC 606 are met. The five core principles will be evaluated for each service provided by the Company and is further supported by applicable guidance in ASC 606 to support the Company’s recognition of revenue.
Revenue is derived primarily from services provided to the Federal government. The Company enters into agreements with customers that create enforceable rights and obligations and for which it is probable that the Company will collect the consideration to which it will be entitled as services and solutions are transferred to the customer. The Company also evaluates whether two or more agreements should be accounted for as one single contract.
When determining the total transaction price, the Company identifies both fixed and variable consideration elements within the contract. The Company estimates variable consideration as the most likely amount to which the Company expects to be entitled, limited to the extent that it is probable that a significant reversal will not occur in a subsequent period.
At contract inception, the Company determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. For most contracts, the customers require the Company to perform several tasks in providing an integrated output and, hence, each of these contracts are deemed as having only one performance obligation. When contracts are separated into multiple performance obligations, the Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised services underlying each performance obligation.
This evaluation requires professional judgment, and it may impact the timing and pattern of revenue recognition. If multiple performance obligations are identified, the Company generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. The Company does not assess whether a contract contains a significant financing component if the Company expects, at contract inception, that the period between when payment by the client and the transfer of promised services to the client occur will be less than one year.
The Company currently generates its revenue from three different types of contractual arrangements: cost plus fixed fee (“CPFF”), firm-fixed-price (“FFP”), and time-and-materials (“T&M”) contracts. The Company generally recognizes revenue over time as control is transferred to the customer, based on the extent of progress towards satisfaction of the performance obligation. The selection of the method used to measure progress requires judgment and is dependent on the contract type and the nature of the goods or services to be provided.
For CPFF contracts, the Company uses input progress measures to derive revenue based on hours worked on contract performance as follows: direct costs plus Defense Contract Audit Agency (“DCAA”) approved provisional burdens plus a fee. The provisional indirect rates are adjusted and billed at actual at year end. Revenue from FFP contracts is generally recognized ratably over the contract term, using a time-based measure of progress, even if billing is based on other metrics or milestones, including specific deliverables. Certain FFP contracts require the use of an input method based on estimated costs to complete. For T&M contracts, the Company uses input progress measures to estimate revenue earned based on hours worked on contract performance at negotiated billing rates, plus direct costs and indirect cost burdens associated with materials and the direct expenses incurred in performance of the contract.
These arrangements generally qualify for the “right-to-invoice” practical expedient where revenue is recognized in proportion to billable consideration. FFP level-of-effort contracts are substantially similar to T&M contracts except that the Company is required to deliver a specified level-of-effort over a stated period. For these contracts, the Company estimates
revenue earned using contract hours worked at negotiated bill rates as the Company delivers the contractually required services.
Revenue generated by contract support service contracts is recognized over time as services are provided, based on the transfer of control. Revenue generated by FFP contracts is recognized over time as performance obligations are satisfied. Most contracts do not contain variable consideration and contract modifications are generally minimal. For these reasons, there is not a significant impact of electing these transition practical expedients.
Revenue generated from contracts with Federal, state, and local governments is recorded over time, rather than at a point in time. Under the contract support services contracts, the Company performs software design work as it is assigned by the customer, and bills the customer, generally semi-monthly, on either a CPFF or T&M basis, as labor hours are expended. Certain other government contracts for software development have specific deliverables and are structured as FFP contracts, which are generally billed as the performance obligations under the contract are met. Revenue recognition under FFP contracts requires judgment to allocate the transaction price to the performance obligations. Contracts may have terms of up to five years.
Contract accounting requires judgment relative to assessing risks and estimating contract revenue, as well as costs and assumptions for schedule and technical issues. Due to the size and nature of contracts, estimates of revenue and costs are subject to a number of variables. For contract change orders, claims, or similar items, judgment is required for estimating the amounts, assessing the potential for realization and determining whether realization is probable. Estimates of total contract revenue and costs are continuously monitored during the term of the contract and are subject to revision as the contract progresses. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known.
The Company accounts for contract costs in accordance with the Accounting Standards Codification ("ASC") 340-40, Other Assets and Deferred Costs - Contracts with Customers. The Company recognizes the cost of sales of a contract as an expense when incurred or at the time a performance obligation is satisfied. The Company recognizes an asset from the costs to fulfill a contract only if the costs relate directly to a contract, the costs generate or enhance resources that will be used in satisfying a performance obligation in the future, and the costs are expected to be recovered. The incremental costs of obtaining a contract are capitalized unless the costs would have been incurred regardless of whether the contract was obtained.
The following table disaggregates the Company’s revenue by contract type for the three months ended September 30:
20252024
Revenue:  
Time and material$4,148,086 $6,254,135 
Firm fixed price619,676 810,812 
Cost plus fixed fee9,851,925 4,543,744 
Total$14,619,687 $11,608,691 
The following table disaggregates the Company’s revenue by contract type for the nine months ended September 30:
20252024
Revenue:  
Time and material$13,186,406 $18,945,698 
Firm fixed price2,045,890 2,323,228 
Cost plus fixed fee25,075,846 13,197,205 
Total$40,308,142 $34,466,131 

Accounting for Income Taxes
Income taxes are accounted for under the asset and liability method. We estimate our income taxes in each of the jurisdictions where the Company operates. This process involves estimating our current tax expense or benefit together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in our Consolidated Balance Sheets. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. When assessing the realizability of deferred tax assets, we consider if it is more likely than not that some or all of the deferred tax assets will not be realized. In making this assessment, we consider the availability of loss carryforwards, projected reversals of deferred tax liabilities, projected future taxable income, and ongoing prudent and feasible tax planning strategies.

We are subject to income taxes in the Federal and state tax jurisdictions based upon our business operations in those jurisdictions. Significant judgment is required in evaluating uncertain tax positions. We record uncertain tax positions in accordance with ASC 740-10, Income Taxes - Overall, on the basis of a two-step process whereby (1) we determine whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) with respect to those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority. Management evaluates its tax positions on a quarterly basis.

The Company files income tax returns in the U.S. Federal tax jurisdiction and various state tax jurisdictions. The Federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed.
Recent Accounting Pronouncements
In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). This update requires disaggregated information about a reporting entity’s effective tax rate reconciliations as well as information on income taxes paid. This update is effective for annual periods beginning in our fiscal year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its financial statement disclosures.
On November 4, 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40) ("ASU 2024-03"). ASU 2024-03 requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 will be effective for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, and will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is evaluating the disclosure impact of ASU 2024-03; however, it does not expect the standard will have a material impact on the Company’s consolidated financial position, results of operations, and/or cash flows.

Other accounting standards updates adopted and/or issued, but not effective until after September 30, 2025, are not expected to have a material effect on the Company’s consolidated financial position, annual results of operations, and/or cash flows.
Balance Sheet Reclassification Adjustment
The Company identified an immaterial error in its annual and interim financial statements for the year ended December 31, 2023 and the first, second, third quarters of 2023, the year ended December 31, 2024, and the first quarter of 2024, whereby additional paid in capital was understated by $274,500 and the obligation to issue common shares account was overstated by $274,500. These immaterial amounts have been adjusted and the corrected balances are reflected in the Company's Consolidated Balance Sheets, Consolidated Statements of Cash Flows, and the Consolidated Statement of Changes in Stockholders' Equity.
v3.25.3
Disposition
9 Months Ended
Sep. 30, 2025
Discontinued Operations and Disposal Groups [Abstract]  
Disposition Disposition
During 2024, the Company completed the following disposition to achieve its business purposes as discussed in Note 1.
MFSI
On September 11, 2024, the Company entered into a stock purchase agreement with Lead-Risk Millenia, LLC (the "Buyer") for the sale of its subsidiary, MFSI (the "MFSI Divestiture"). The stock purchase agreement, approved by the Board of Directors on September 13, 2024, was for the purchase and sale of 100% of the issued and outstanding stock of MFSI, which became effective on September 16, 2024. The stock purchase agreement required an initial cash payment of $15,000. Additionally, the Company will receive future consideration equal to 6% of all revenue generated by MFSI until September 30, 2029, or until total payments reach $705,000, whichever comes first. As part of the MFSI Divestiture, the Company retained all of MFSI's cash deposits and accounts receivable in excess of $150,000.
Management estimated the present value of future consideration to be received, recognizing short- and long-term components of a receivable, which we will accrete over time and reassess periodically. An 8.5% discount rate was applied to calculate the present value of the receivable, totaling $160,221 ("Anticipated Receivable"). The Anticipated Receivable is revalued each quarter. The Company recorded a gain of $39,234 from the MFSI Divestiture. The balance of the Anticipated Receivable, accounts receivable in excess of $150,000, and any payments made by the Company on behalf of the Buyer, are reflected in Due from Buyer on the Consolidated Balance Sheets.
After considering qualitative and quantitative aspects of MFSI and its sale relative to the guidance of ASC 205-20, Presentation of Financial Statements - Discontinued Operations, Management concluded MFSI should not be reported or disclosed as a discontinued operation. Further, since MFSI represented less than 5% of the total revenue for the Company, it was deemed immaterial to the Company's financial statements, and as such, pro forma financial statements are not required.
v3.25.3
Fixed Assets
9 Months Ended
Sep. 30, 2025
Property, Plant and Equipment [Abstract]  
Fixed Assets Fixed Assets
Fixed assets consisted of the following as of September 30, 2025, and December 31, 2024:
September 30, 2025December 31, 2024
Equipment and software$405,988 $261,408 
Furniture43,119 43,119 
Automobiles43,928 43,928 
Leasehold improvements192,959 192,959 
Total fixed assets685,994 541,414 
Accumulated depreciation (445,851)(385,303)
Fixed assets, net$240,143 $156,111 
Depreciation expense for the three and nine months ended September 30, 2025, was $18,753 and $57,892, and depreciation expense for the three and nine months ended September 30, 2024, was $38,855 and $119,942, respectively.
v3.25.3
Intangible Assets and Goodwill
9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets and Goodwill
Intangible assets consisted of the following as of September 30, 2025, and December 31, 2024:
September 30,
2025
December 31,
2024
Customer relationships
4.5– 15 years
$11,613,000 $11,613,000 
Tradename15 years783,000 783,000 
Trademark
10-15 years
533,864 533,864 
Backlog
2-5 years
3,210,000 3,210,000 
Non-compete agreement
3-5 years
680,000 680,000 
16,819,864 16,819,864 
Accumulated amortization(11,092,728)(10,026,114)
Intangible assets, net$5,727,136 $6,793,750 
The intangible assets with the exception of the trademarks were recorded as part of the acquisitions of Corvus, Merrison, SSI, LSG, and GTMR. Amortization expense for the three and nine months ended September 30, 2025 was $355,537 and $1,066,611, respectively, and amortization expense for the three and nine months ended September 30, 2024 was $517,669 and $1,603,611, respectively. The intangible assets are being amortized based on the estimated future lives as noted above.
Future amortization of the intangible assets for the next five years as of September 30 are as follows:
Remainder of the year ending December 31, 2025$355,537 
Year ending 20261,218,182 
Year ending 20271,014,558 
Year ending 2028528,784 
Year ending 2029441,568 
Year ending 2030 and thereafter2,168,507 
Total$5,727,136 
The goodwill rollforward for the nine months ended September 30, 2025, reflects no changes, as follows:
CorvusSSITotal
December 31, 2024$1,958,741 $8,718,093 $10,676,834 
September 30, 2025$1,958,741 $8,718,093 $10,676,834 
When the Company acquires a controlling financial interest through a business combination, the Company uses the acquisition method of accounting to allocate the purchase consideration to the assets acquired and liabilities assumed, which are recorded at fair value. Any excess of purchase consideration over the net fair value of the net assets acquired is recognized as goodwill. There were no additions of goodwill for the nine months ended September 30, 2025.
v3.25.3
Notes Payable
9 Months Ended
Sep. 30, 2025
Notes Payable [Abstract]  
Notes Payable Notes Payable
Our notes payable consists of the following as of September 30, 2025 and December 31, 2024:
September 30, 2025December 31,
2024
Note payable dated February 22, 2024, maturing December 15, 2027 (a)$2,000,000 $6,000,000 
Promissory note payable (b)— 2,000,000 
Total Notes Payable $2,000,000 $8,000,000 


(a)On February 22, 2024, as a result of amending the previous notes, as detailed Part II, Item 8 “Financial Statements and Supplementary Data”, Note 7 "Notes Payable", of our Annual Report on Form 10-K for the year-ended December 31, 2024, the Company entered into a new note (the "2024 Eisiminger Note"), with a principal balance of $6,000,000, maturing on August 31, 2026, and bearing interest at 7.5% per annum until February 1, 2025, after which the interest rate will increase to 8% per annum. On April 17, 2025, the Company amended the 2024 Eisiminger Note, providing for a $2,000,000 principal payment, extending the maturity date to December 15, 2027, and increasing the interest rate to 10%. Subsequently, on August 4, 2025, the Company made an additional $2,000,000 principal payment.
(b)On February 22, 2024, the Company and the Buckhout Charitable Remainder Trust entered into a new note payable in the principal amount of $2,400,000 (the "Buckhout February 2024 Note") which was scheduled to mature on August 31, 2026, and accrue interest at a per annum rate of 5% through January 1, 2025, 8% per annum through January 1, 2026, and 12% per annum thereafter. The principal amount was amortized at the rate of $100,000 per month, commencing in September 2024. On June 2, 2025, the Company fully repaid the remaining principal balance of the Buckhout February 2024 Note, along with two days of accrued interest for the month of June. The repayment fully extinguished the related liability.
Interest expense for the three and nine months ended September 30, 2025 was $69,589 and $349,507, respectively, and $181,474 and $565,440 for the three and nine months ended September 30, 2024, respectively. Accrued interest on the notes payable as of September 30, 2025 and September 30, 2024 was $0.
Future principal payments are scheduled to be zero in 2025, with the full principal balance due in December 2027.
v3.25.3
Note Payable - Related Party
9 Months Ended
Sep. 30, 2025
NOTE PAYABLE RELATED PARTY [Abstract]  
Note Payable - Related Party Note Payable – Related Party
The Company entered into a note payable with a related party in August 2021 with balances as of September 30, 2025 and December 31, 2024, as follows:
September 30,
2025
December 31,
2024
Note payable at 5%, amended to mature on March 31, 2026
$400,000 $400,000 
On February 16, 2024, the Company entered into a letter agreement to (i) extend the maturity date from December 31, 2024 to August 1, 2025 and (ii) require subsequent monthly principal payments of $50,000 for eight months commencing on the maturity date, with the final payment by March 31, 2026. On August 1, 2025, the Company further extended the maturity date to March 1, 2026, maintaining the $50,000 monthly amortization for eight months beginning in March 2026. All other terms of the note payable remain unchanged. As a result, $350,000 is reflected in current liabilities and $50,000 is reflected in noncurrent liabilities.
Interest expense for the three and nine months ended September 30, 2025, was $5,041 and $14,959, respectively, and $5,027 and $14,973 for the three and nine months ended September 30, 2024, respectively.
v3.25.3
Revolving Credit Facility
9 Months Ended
Sep. 30, 2025
Debt Disclosure [Abstract]  
Revolving Credit Facility Revolving Credit Facility
On April 4, 2022, the Company obtained a $950,000 revolving credit facility with Live Oak Banking Company (“Live Oak Bank”), maturing March 28, 2029. On February 22, 2024, the Company replaced this facility with a new $4,000,000 revolving credit facility maturing February 22, 2025 ("New Live Oak Revolver"). The outstanding balance of approximately $625,000 was rolled over, and an additional $904,793 was advanced. As of December 31, 2024, $1,999,944 was outstanding under the new facility.
Effective August 15, 2024, the Company amended the New Live Oak Revolver, requiring a $250,000 collateral account, increasing borrowing base reporting to twice monthly, and reducing borrowing capacity from $4,000,000 to $2,000,000. On February 13, 2025, the Company fully repaid the $1,999,944 balance plus interest, after which the line of credit was closed and the restricted cash released. No obligations remain under the facility.
Interest expense for the nine months ended September 30, 2025 and 2024, was $28,658 and $109,512, respectively.
v3.25.3
Due To Seller
9 Months Ended
Sep. 30, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Due To Seller Due to Seller
As part of the acquisition of SSI (the "SSI Acquisition"), the Company was obligated to pay an earnout contingent on the results of operations of SSI through August 2023. On February 15, 2024, the Company entered into an agreement with the former shareholders of SSI concerning the amount and timing of the contingent earnout included in total consideration for the SSI Acquisition which closed in August 2021. The parties agreed to settle the amount for a total of $720,000, with an initial payment of $180,000 that was made by the Company at signing of the agreement, plus starting in March 2024, monthly payments of $20,000 plus interest payable at 5% per annum for 27 months. As a result, $160,000 is recorded as Due to Seller in current liabilities as of September 30, 2025. Prior to the February 15, 2024 agreement, this earnout was recorded as Contingent Earnout on the Consolidated Balance Sheets. The Company paid the remaining principal and interest in November 2025, reducing the Due to Seller balance to zero. See Note 14, "Subsequent Event", for further details.
v3.25.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Preferred Stock
The Company has 50,000,000 shares of preferred stock authorized. The Company has designated a Series A Preferred Stock, a Series B Preferred Stock, and a Series C Preferred Stock.
Series A Preferred Stock
The Company has designated 10,000,000 shares of Series A Preferred Stock, par value of $0.0001. As of September 30, 2025 and December 31, 2024, the Company has 5,875,000 shares of Series A Preferred Stock issued and outstanding, which is convertible into 587,500 shares of the Company's common stock.
For the nine months ended September 30, 2025 and 2024, the Company recognized $54,808 and $54,808, respectively, in Series A dividends, all of which have been paid as of September 30, 2025.
Series B Preferred Stock
The Company has designated 10,000,000 shares of Series B Preferred Stock, par value of $0.0001. As of September 30, 2025 and December 31, 2024, the Company has 0 shares of Series B Preferred Stock issued and outstanding.
Series C Preferred Stock
The Company has designated 10,000,000 shares of Series C Preferred Stock, par value of $0.0001. As of September 30, 2025, the Company has 570,000 shares of Series C Preferred Stock issued and outstanding, which is convertible into 356,250 shares of the Company's common stock. As of December 31, 2024, the Company had 770,000 shares of Series C Preferred Stock issued and outstanding.
For the nine months ended September 30, 2025 and 2024, the Company recognized $25,815 and $34,650 in Series C dividends, all of which have been paid as of September 30, 2025.
Common Stock
The Company has 3,000,000,000 shares of common stock, par value $0.0001 authorized. The Company has 94,612,750 and 77,076,129 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively.
On September 17, 2025, the Company filed a registration statement on Form S-8 (File No. 333-290331) to register an aggregate of 3,000,000 shares of the Company's common stock to be issued pursuant to the Castellum, Inc. 2025 Employee Stock Purchase Plan.

On September 17, 2025, the Company filed a registration statement on Form S-8 (File No. 333-290332) to register an aggregate of 9,000,000 shares of the Company's common stock to be issued pursuant to the Castellum, Inc. Second Amended 2021 Stock Incentive Plan.
On January 25, 2024, the Company entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 5,243,967 shares of the Company’s common stock, at a purchase price of $0.32 per share and (ii) 3,193,534 pre-funded warrants (the “Pre-funded Warrant(s)”) to purchase up to an aggregate of 3,193,534 shares of common stock for aggregate gross proceeds to the Company of approximately $2.7 million, before deducting the placement agent fees and estimated offering expenses payable by the Company (the “Registered Offering”). The Pre-funded Warrants were sold at an offering price of $0.319 per Pre-funded Warrant and are exercisable at a price of $0.001 per share.

In a concurrent private placement, the Company agreed to issue to the same institutional investor, for each ordinary share and Pre-funded Warrant purchased in the offering, an additional ordinary share purchase warrant (“Regular Warrants”). The Regular Warrants have an exercise price of $0.35 and were exercisable to purchase an aggregate of 8,437,501 shares of common stock. The Regular Warrants were exercisable for five years. All Pre-funded and Regular Warrants have been exercised as of September 30, 2025.
On January 3, 2025, a member of the Company’s Board of Directors, exercised stock options at $0.210 per share for 110,028 shares of common stock. On August 21, 2025, a member of the Company's Board of Directors, exercised stock options at $0.210 per share for 125,000 shares of common stock.

In January 2025, two holders of the Company’s Series C Preferred Stock, converted 200,000 shares of Series C Preferred Stock into 125,000 shares of common stock at a conversion rate of 0.625 shares of common stock per share of Series C Preferred Stock.

On February 12, 2025, an investor exercised an aggregate of 1,080,717 warrants to purchase 1,080,717 shares of the Company’s common stock which resulted in proceeds to the Company of $1. Prior to this exercise, the treatment of these warrants was evaluated under ASC 260-10, Earnings Per Share — Overall. Under this guidance, shares issuable for little or no cash consideration are considered outstanding common shares and are included in the computation of basic earnings per share from the date they are granted. Accordingly, the exercise of these warrants does not impact the Company's earnings per share calculation.

On January 10, 2025, the Company filed a universal shelf registration on Form S-3 (File No. 333-284205), which was declared effective by the SEC on January 24, 2025, pursuant to which the Company may offer and sell up to $100,000,000 of equity and debt securities.

On March 19, 2025, the Company closed on the public offering (the "March 2025 Public Offering") of 4,500,000 units ("Unit(s)") at a public offering price of $1.00 per Unit. Each Unit consisted of one share of common stock and one warrant to purchase one share of common stock (the "March 2025 Warrants"). The March 2025 Warrants were immediately exercisable at $1.08 per share and expired 60 days from the date of issuance. The shares of common stock and March 2025 Warrants were immediately separable and issued separately. Gross proceeds from the March 2025 Public Offering were approximately $4.5 million before deducting placement agent fees and offering expenses. Castellum used the net proceeds of the March 2025 Offering for working capital and general corporate purposes.

On June 13, 2025, the Company closed on the public offering (the "June 2025 Public Offering") of 4,166,667 units ("Unit(s)") at a public offering price of $1.20 per Unit. Each Unit consists of one share of common stock and one warrant to purchase one share of common stock (the "June 2025 Warrants"). The June 2025 Warrants were immediately exercisable at $1.22 per share and expired 60 days from the date of issuance. The shares of common stock and June 2025 Warrants were immediately separable and issued separately. Gross proceeds from the June 2025 Public Offering were approximately $5.0 million before deducting placement agent fees and offering expenses. Castellum used the net proceeds of the June 2025 Public Offering for working capital and general corporate purposes.

As of September 30, 2025, 1,755,543 of the March 2025 Warrants issued were exercised at $1.08 per share, for gross proceeds of $1.90 million before deducting placement agent fees. The remaining 2,744,457 March 2025 Warrants have expired as of September 30, 2025.

As of September 30, 2025, 3,673,666 of the June 2025 Warrants issued were exercised at $1.22 per share, for gross proceeds of $4.48 million before deducting placement agent fees. The remaining 493,001 June 2025 Warrants have expired as of September 30, 2025.
During the nine months ended September 30, 2025, the Company recorded an obligation to issue 515,464 restricted shares of common stock, that vest ratably over a period of one year, to its Board of Directors (the "Board") for their service on the Board from January 1, 2024, through June 30, 2024. The total expense booked to record this obligation was $146,768. On June 11, 2025, the Board agreed to a cash payment totaling $146,700, which was paid out on June 17, 2025, and the obligation to issue shares was reduced to zero.
During the nine months ended September 30, 2025, 17,536,621 shares of common stock were issued.
Warrants
The Pre-funded Warrants were immediately exercisable and did not have an expiration date. As noted above, the Company sold Pre-funded Warrants to purchase up to an aggregate of 3,193,534 shares of common stock at an offering price of $0.319 per Pre-funded Warrant, which are exercisable at a price of $0.001 per share. As previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2024, all Pre-funded Warrants have been exercised.

The Regular Warrants became exercisable on March 20, 2024, upon effectiveness of shareholder approval which was obtained on February 12, 2024. The Regular Warrants would have expired on March 20, 2029, and had an exercise price of
$0.35 per share. 6,437,501 of the Regular Warrants were exercised in 2024. The remaining 2,000,000 warrants were exercised in February of 2025 to purchase 2,000,000 shares of the Company’s common stock which resulted in aggregate proceeds to the Company of $700,000. All warrants held by this investor have now been fully exercised.

On February 12, 2025, an investor exercised an aggregate of 1,080,717 warrants to purchase 1,080,717 shares of the Company’s common stock which resulted in proceeds to the Company of $1. The treatment of these warrants was accessed under ASC 260-10, Earnings Per Share—Overall, where shares issuable for little or no cash consideration shall be considered outstanding common shares and are included in the computation of basic earnings per share since they were originally granted.
Of the 4,500,000 March 2025 Warrants issued during the March Public Offering, 1,755,543 warrants were exercised at $1.08 per share prior to September 30, 2025. The remaining 2,744,457 warrants expired on May 19, 2025.
Of the 4,166,667 June 2025 Warrants issued during the June 2025 Public Offering, 3,673,666 warrants were exercised at $1.22 per share prior to September 30, 2025. The remaining 493,001 warrants expired on August 12, 2025.
The following table represents a summary of warrants for the nine months ended September 30, 2025 and the year ended December 31, 2024:
Nine Months Ended
September 30, 2025
Year Ended
December 31, 2024
NumberWeighted
Average
Exercise
Price
NumberWeighted
Average
Exercise
Price
Beginning balance8,744,698$1.40 7,444,698$1.68 
Granted8,666,6671.15 11,631,0350.34 
Exercised(8,509,926)0.83 (10,331,035)0.41 
Expired(3,247,458)1.08 — — 
Ending balance5,653,981$2.05 8,744,698$1.40 
Warrants exercisable 5,653,9818,744,698
Intrinsic value of warrants$53,293 $6,661,661 
Weighted Average Remaining Contractual Life (Years)3.373.86
Options
The Company on November 9, 2021, approved the 2021 Stock Incentive Plan (the "Plan"), that authorized the Company to issue up to 2,500,000 shares of the Company's common stock in the form of restricted stock, stock options, and other stock awards as set forth in the Plan. On November 9, 2023 the Board of Directors approved an amendment to the Plan to increase the aggregate number of shares available for issuance from 2,500,000 to 6,000,000 (the "Amended Plan"), which was approved by the Company's shareholders at its annual meeting on May 29, 2024.
On March 11, 2025, the Board approved an amendment to the Amended Plan to further increase the aggregate number of shares available for issuance from 6,000,000 to 9,000,000 (the "Second Plan Amendment" and the "Second Amended Plan"), which was approved by the Company's shareholders at the Company's 2025 annual meeting of shareholders held on May 28, 2025. As of September, 30, 2025, 5,887,500 stock options have been granted under the Amended Plan.
The following represents a summary of options for the Second Amended Plan and additional options granted outside of the Second Amended Plan, for the nine months ended September 30, 2025 and the year ended December 31, 2024:
NumberWeighted
Average
Exercise
Price
Weighted-Average Remaining Contractual Term (in Years)Weighted
Average
Fair Value
Outstanding December 31, 20249,515,000 $2.03 3.89$3.12 
Granted1,855,0001.076.301.05
Exercised(250,000)0.2100.19
Forfeited(687,500)0.802.00
Outstanding September 30, 202510,432,500$1.99 4.08$2.82 
As of September 30, 2025
Vested and exercisable7,601,835$2.09 4.31$2.47 
During the nine months ended September 30, 2025, the Company recognized $2,103,344 of noncash stock-based compensation related to the vesting of service-based stock options. 250,000 options were exercised during the nine months ended September 30, 2025 at $0.21 per share for 110,028 of common stock.
The fair value of each option is estimated using the Black-Scholes valuation model. Changes to these inputs could produce a significantly higher or lower fair value measurement. The following assumptions were used for the periods as follows:
Nine Months Ended
September 30, 2025
Year
Ended
December 31, 2024
Expected term7 years7 years
Expected volatility
164.63% – 169.72%
123.05% – 124.33%
Expected dividend yield— — 
Risk-free interest rate
4.14% – 4.51%
3.89% - 4.45%
v3.25.3
Fair Value
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. U.S. GAAP sets forth a three-level fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three levels are as follows:
Level 1 – defined as observable inputs, such as quoted market prices in active markets.
Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.
Level 3 – defined as unobservable inputs in which little or no market data exists, therefore, requiring an entity to develop its own assumptions.
Our financial assets and liabilities subject to the three-level fair value hierarchy consist principally of cash, accounts receivable, accounts payable, contingent consideration, and derivative liabilities. The estimated fair value of cash and cash equivalents, accounts receivable, and accounts payable approximates their carrying value.
On April 4, 2022, the Company issued common stock, a convertible note, and warrants in a SPA with Crom (respectively, the "2022 Crom Note", the "2022 Crom Warrants, and the “2022 Crom SPA”). The Company had evaluated the conversion option liability in the 2022 Crom Note and the 2022 Crom Warrant to determine proper accounting treatment and determined them to be derivative liabilities (the "Derivative Liabilities").
On February 13, 2023, the 2022 Crom SPA was terminated through an induced conversion thereby extinguishing the conversion option liability associated with the 2022 Crom Note; the 2022 Crom Warrants were not affected. The Derivative Liabilities in the tables below include the 2022 Crom Warrants. Refer to Note 10, “Stockholders’ Equity”, for more detail.

The Company recognized a liability for the estimated fair value of the 2022 Crom Warrants. The estimated fair value of the liability was calculated using a binomial pricing model with key input variables by an independent third party, as of the date of issuance, with changes in fair value recorded as gains or losses on revaluation in other income (expense). The Company determined that the significant inputs used to value the 2022 Crom Warrants fall within Level 3 of the fair value hierarchy.

In connection with the divestiture of MFSI , as discussed in Note 3, "Disposition", Management estimated the present value of future consideration to be received, using a probability-weighted analysis to determine the amount of the receivable and applying a discount rate that captures the risks associated with the duration of the consideration. The Company determined that the significant inputs used to value the Anticipated Receivable fall within Level 3 of the fair value hierarchy.
The following tables present the Company's financial instruments that are measured at fair value on a recurring basis:
Fair Value Measurements at September 30, 2025
Level 1Level 2Level 3Total
Anticipated Receivable $— $— $160,221 $160,221 
2022 Crom Warrants$— $— $348,000 $348,000 
Fair Value Measurements at December 31, 2024
Level 1Level 2Level 3Total
Anticipated Receivable$— $— $265,739 $265,739 
2022 Crom Warrants$— $— $883,000 $883,000 
Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of the 2022 Crom Warrants is estimated using a binomial valuation model. The following assumptions were used for the period as follows:
September 30,
2025
Expected term - warrants
1.51 years
Stock price as of measurement date$1.09 
Volatility (observed)
147.40%
Incremental discount5.0 %
Selected volatility – post haircut
133.1%
Risk-free interest rate
3.61%
v3.25.3
Concentrations
9 Months Ended
Sep. 30, 2025
Risks and Uncertainties [Abstract]  
Concentrations Concentrations
Concentration of Credit Risk. The Company’s customer base is concentrated with a relatively small number of customers. The Company does not generally require collateral or other security to support accounts receivable. To reduce credit risk, the Company performs ongoing credit evaluations on its customers’ financial condition. The Company establishes allowance for credit losses based upon factors surrounding the credit risk of customers, historical trends, and other information.
For the nine months ended September 30, 2025 and 2024, the Company had three customers (all parts of the U.S. government) representing 72% and 52% of revenue earned, respectively. Any customer that represents 10% or greater of total revenue represents a risk. The Company also has three customers that represent 72% and four customers (all parts of the U.S. government) that represent 65% of the total accounts receivable as of September 30, 2025, and December 31, 2024, respectively.
v3.25.3
Income Taxes
9 Months Ended
Sep. 30, 2025
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company's quarterly provision for income taxes is measured using an estimated annual effective tax rate adjusted for discrete items that occur within the quarter. The effective income tax rate was 20.40% and (16.75)% for the three months ended September 30, 2025, and 2024, respectively. The change in the effective tax was primarily due to nondeductible stock compensation, disallowed expenses, state taxes and the increase in valuation allowance in the current year as the Company maintains a full valuation allowance against the deferred tax assets. The effective tax rate was (10.80)% and —% for the nine months ended September 30, 2025 and 2024, respectively. The change in the effective tax rate was primarily due to the nondeductible stock compensation, disallowed expenses, state taxes, and the increase in valuation allowance.
v3.25.3
Subsequent Events
9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
Subsequent to September 30, 2025, and prior to the filing date of November 7, 2025, the Company fully settled the Due to Seller obligation, paying $140,000 plus accrued interest, resulting in a zero balance.
v3.25.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.3
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Basis of Presentation and Basis of Presentation for Interim Periods.
Basis of Presentation
The accompanying consolidated financial statements, including the notes, include the accounts of the Company and its wholly-owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). All intercompany balances and transactions have been eliminated in consolidation.
Basis of Presentation for Interim Periods
Certain information and footnote disclosures normally included for the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted for the interim periods presented. We believe that the unaudited interim financial statements include all adjustments (which are normal and recurring in nature) necessary to present fairly our financial position and the results of operations and cash flows for the periods presented.
The results of operations for the interim periods presented are not necessarily indicative of results that may be expected for the year or future periods. The financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K for the year then ended. We have continued to follow the accounting policies set forth in those financial statements.
Business Segments
Business Segments
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM, the Chief Executive Officer, reviews consolidated results of operations to make decisions. The Company maintains one operating and reportable segment, which is the delivery of products and
services in the areas of information technology, electronic warfare, information warfare, and cybersecurity in the governmental and commercial markets.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
Revenue Recognition
The Company accounts for revenue in accordance with ASC 606, Revenue from Contracts with Customers ("ASC 606"). The Company accounts for a contract with a customer that is within the scope of this Topic only when the five steps of revenue recognition under ASC 606 are met. The five core principles will be evaluated for each service provided by the Company and is further supported by applicable guidance in ASC 606 to support the Company’s recognition of revenue.
Revenue is derived primarily from services provided to the Federal government. The Company enters into agreements with customers that create enforceable rights and obligations and for which it is probable that the Company will collect the consideration to which it will be entitled as services and solutions are transferred to the customer. The Company also evaluates whether two or more agreements should be accounted for as one single contract.
When determining the total transaction price, the Company identifies both fixed and variable consideration elements within the contract. The Company estimates variable consideration as the most likely amount to which the Company expects to be entitled, limited to the extent that it is probable that a significant reversal will not occur in a subsequent period.
At contract inception, the Company determines whether the goods or services to be provided are to be accounted for as a single performance obligation or as multiple performance obligations. For most contracts, the customers require the Company to perform several tasks in providing an integrated output and, hence, each of these contracts are deemed as having only one performance obligation. When contracts are separated into multiple performance obligations, the Company allocates the total transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised services underlying each performance obligation.
This evaluation requires professional judgment, and it may impact the timing and pattern of revenue recognition. If multiple performance obligations are identified, the Company generally uses the cost plus a margin approach to determine the relative standalone selling price of each performance obligation. The Company does not assess whether a contract contains a significant financing component if the Company expects, at contract inception, that the period between when payment by the client and the transfer of promised services to the client occur will be less than one year.
The Company currently generates its revenue from three different types of contractual arrangements: cost plus fixed fee (“CPFF”), firm-fixed-price (“FFP”), and time-and-materials (“T&M”) contracts. The Company generally recognizes revenue over time as control is transferred to the customer, based on the extent of progress towards satisfaction of the performance obligation. The selection of the method used to measure progress requires judgment and is dependent on the contract type and the nature of the goods or services to be provided.
For CPFF contracts, the Company uses input progress measures to derive revenue based on hours worked on contract performance as follows: direct costs plus Defense Contract Audit Agency (“DCAA”) approved provisional burdens plus a fee. The provisional indirect rates are adjusted and billed at actual at year end. Revenue from FFP contracts is generally recognized ratably over the contract term, using a time-based measure of progress, even if billing is based on other metrics or milestones, including specific deliverables. Certain FFP contracts require the use of an input method based on estimated costs to complete. For T&M contracts, the Company uses input progress measures to estimate revenue earned based on hours worked on contract performance at negotiated billing rates, plus direct costs and indirect cost burdens associated with materials and the direct expenses incurred in performance of the contract.
These arrangements generally qualify for the “right-to-invoice” practical expedient where revenue is recognized in proportion to billable consideration. FFP level-of-effort contracts are substantially similar to T&M contracts except that the Company is required to deliver a specified level-of-effort over a stated period. For these contracts, the Company estimates
revenue earned using contract hours worked at negotiated bill rates as the Company delivers the contractually required services.
Revenue generated by contract support service contracts is recognized over time as services are provided, based on the transfer of control. Revenue generated by FFP contracts is recognized over time as performance obligations are satisfied. Most contracts do not contain variable consideration and contract modifications are generally minimal. For these reasons, there is not a significant impact of electing these transition practical expedients.
Revenue generated from contracts with Federal, state, and local governments is recorded over time, rather than at a point in time. Under the contract support services contracts, the Company performs software design work as it is assigned by the customer, and bills the customer, generally semi-monthly, on either a CPFF or T&M basis, as labor hours are expended. Certain other government contracts for software development have specific deliverables and are structured as FFP contracts, which are generally billed as the performance obligations under the contract are met. Revenue recognition under FFP contracts requires judgment to allocate the transaction price to the performance obligations. Contracts may have terms of up to five years.
Contract accounting requires judgment relative to assessing risks and estimating contract revenue, as well as costs and assumptions for schedule and technical issues. Due to the size and nature of contracts, estimates of revenue and costs are subject to a number of variables. For contract change orders, claims, or similar items, judgment is required for estimating the amounts, assessing the potential for realization and determining whether realization is probable. Estimates of total contract revenue and costs are continuously monitored during the term of the contract and are subject to revision as the contract progresses. From time to time, facts develop that require revisions of revenue recognized or cost estimates. To the extent that a revised estimate affects the current or an earlier period, the cumulative effect of the revision is recognized in the period in which the facts requiring the revision become known.
The Company accounts for contract costs in accordance with the Accounting Standards Codification ("ASC") 340-40, Other Assets and Deferred Costs - Contracts with Customers. The Company recognizes the cost of sales of a contract as an expense when incurred or at the time a performance obligation is satisfied. The Company recognizes an asset from the costs to fulfill a contract only if the costs relate directly to a contract, the costs generate or enhance resources that will be used in satisfying a performance obligation in the future, and the costs are expected to be recovered. The incremental costs of obtaining a contract are capitalized unless the costs would have been incurred regardless of whether the contract was obtained.
The following table disaggregates the Company’s revenue by contract type for the three months ended September 30:
20252024
Revenue:  
Time and material$4,148,086 $6,254,135 
Firm fixed price619,676 810,812 
Cost plus fixed fee9,851,925 4,543,744 
Total$14,619,687 $11,608,691 
The following table disaggregates the Company’s revenue by contract type for the nine months ended September 30:
20252024
Revenue:  
Time and material$13,186,406 $18,945,698 
Firm fixed price2,045,890 2,323,228 
Cost plus fixed fee25,075,846 13,197,205 
Total$40,308,142 $34,466,131 
Accounting for Income Taxes
Accounting for Income Taxes
Income taxes are accounted for under the asset and liability method. We estimate our income taxes in each of the jurisdictions where the Company operates. This process involves estimating our current tax expense or benefit together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included in our Consolidated Balance Sheets. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. When assessing the realizability of deferred tax assets, we consider if it is more likely than not that some or all of the deferred tax assets will not be realized. In making this assessment, we consider the availability of loss carryforwards, projected reversals of deferred tax liabilities, projected future taxable income, and ongoing prudent and feasible tax planning strategies.

We are subject to income taxes in the Federal and state tax jurisdictions based upon our business operations in those jurisdictions. Significant judgment is required in evaluating uncertain tax positions. We record uncertain tax positions in accordance with ASC 740-10, Income Taxes - Overall, on the basis of a two-step process whereby (1) we determine whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) with respect to those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority. Management evaluates its tax positions on a quarterly basis.

The Company files income tax returns in the U.S. Federal tax jurisdiction and various state tax jurisdictions. The Federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
In December 2023, the FASB issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). This update requires disaggregated information about a reporting entity’s effective tax rate reconciliations as well as information on income taxes paid. This update is effective for annual periods beginning in our fiscal year ending December 31, 2025. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its financial statement disclosures.
On November 4, 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40) ("ASU 2024-03"). ASU 2024-03 requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. ASU 2024-03 will be effective for annual periods beginning January 1, 2027, and interim periods beginning January 1, 2028, and will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is evaluating the disclosure impact of ASU 2024-03; however, it does not expect the standard will have a material impact on the Company’s consolidated financial position, results of operations, and/or cash flows.

Other accounting standards updates adopted and/or issued, but not effective until after September 30, 2025, are not expected to have a material effect on the Company’s consolidated financial position, annual results of operations, and/or cash flows.
Balance Sheet Reclassification Adjustment
Balance Sheet Reclassification Adjustment
The Company identified an immaterial error in its annual and interim financial statements for the year ended December 31, 2023 and the first, second, third quarters of 2023, the year ended December 31, 2024, and the first quarter of 2024, whereby additional paid in capital was understated by $274,500 and the obligation to issue common shares account was overstated by $274,500. These immaterial amounts have been adjusted and the corrected balances are reflected in the Company's Consolidated Balance Sheets, Consolidated Statements of Cash Flows, and the Consolidated Statement of Changes in Stockholders' Equity
v3.25.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Company's Revenue By Contract Type
The following table disaggregates the Company’s revenue by contract type for the three months ended September 30:
20252024
Revenue:  
Time and material$4,148,086 $6,254,135 
Firm fixed price619,676 810,812 
Cost plus fixed fee9,851,925 4,543,744 
Total$14,619,687 $11,608,691 
The following table disaggregates the Company’s revenue by contract type for the nine months ended September 30:
20252024
Revenue:  
Time and material$13,186,406 $18,945,698 
Firm fixed price2,045,890 2,323,228 
Cost plus fixed fee25,075,846 13,197,205 
Total$40,308,142 $34,466,131 
v3.25.3
Fixed Assets (Tables)
9 Months Ended
Sep. 30, 2025
Property, Plant and Equipment [Abstract]  
Summary of Fixed Assets
Fixed assets consisted of the following as of September 30, 2025, and December 31, 2024:
September 30, 2025December 31, 2024
Equipment and software$405,988 $261,408 
Furniture43,119 43,119 
Automobiles43,928 43,928 
Leasehold improvements192,959 192,959 
Total fixed assets685,994 541,414 
Accumulated depreciation (445,851)(385,303)
Fixed assets, net$240,143 $156,111 
v3.25.3
Intangible Assets and Goodwill (Tables)
9 Months Ended
Sep. 30, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following as of September 30, 2025, and December 31, 2024:
September 30,
2025
December 31,
2024
Customer relationships
4.5– 15 years
$11,613,000 $11,613,000 
Tradename15 years783,000 783,000 
Trademark
10-15 years
533,864 533,864 
Backlog
2-5 years
3,210,000 3,210,000 
Non-compete agreement
3-5 years
680,000 680,000 
16,819,864 16,819,864 
Accumulated amortization(11,092,728)(10,026,114)
Intangible assets, net$5,727,136 $6,793,750 
Schedule of Future Amortization of Intangible Assets
Future amortization of the intangible assets for the next five years as of September 30 are as follows:
Remainder of the year ending December 31, 2025$355,537 
Year ending 20261,218,182 
Year ending 20271,014,558 
Year ending 2028528,784 
Year ending 2029441,568 
Year ending 2030 and thereafter2,168,507 
Total$5,727,136 
Schedule of Goodwill
The goodwill rollforward for the nine months ended September 30, 2025, reflects no changes, as follows:
CorvusSSITotal
December 31, 2024$1,958,741 $8,718,093 $10,676,834 
September 30, 2025$1,958,741 $8,718,093 $10,676,834 
v3.25.3
Notes Payable (Tables)
9 Months Ended
Sep. 30, 2025
Notes Payable [Abstract]  
Schedule of notes payable
Our notes payable consists of the following as of September 30, 2025 and December 31, 2024:
September 30, 2025December 31,
2024
Note payable dated February 22, 2024, maturing December 15, 2027 (a)$2,000,000 $6,000,000 
Promissory note payable (b)— 2,000,000 
Total Notes Payable $2,000,000 $8,000,000 


(a)On February 22, 2024, as a result of amending the previous notes, as detailed Part II, Item 8 “Financial Statements and Supplementary Data”, Note 7 "Notes Payable", of our Annual Report on Form 10-K for the year-ended December 31, 2024, the Company entered into a new note (the "2024 Eisiminger Note"), with a principal balance of $6,000,000, maturing on August 31, 2026, and bearing interest at 7.5% per annum until February 1, 2025, after which the interest rate will increase to 8% per annum. On April 17, 2025, the Company amended the 2024 Eisiminger Note, providing for a $2,000,000 principal payment, extending the maturity date to December 15, 2027, and increasing the interest rate to 10%. Subsequently, on August 4, 2025, the Company made an additional $2,000,000 principal payment.
(b)On February 22, 2024, the Company and the Buckhout Charitable Remainder Trust entered into a new note payable in the principal amount of $2,400,000 (the "Buckhout February 2024 Note") which was scheduled to mature on August 31, 2026, and accrue interest at a per annum rate of 5% through January 1, 2025, 8% per annum through January 1, 2026, and 12% per annum thereafter. The principal amount was amortized at the rate of $100,000 per month, commencing in September 2024. On June 2, 2025, the Company fully repaid the remaining principal balance of the Buckhout February 2024 Note, along with two days of accrued interest for the month of June. The repayment fully extinguished the related liability.
v3.25.3
Note Payable - Related Party (Tables)
9 Months Ended
Sep. 30, 2025
NOTE PAYABLE RELATED PARTY [Abstract]  
Schedule of notes payable to related party
The Company entered into a note payable with a related party in August 2021 with balances as of September 30, 2025 and December 31, 2024, as follows:
September 30,
2025
December 31,
2024
Note payable at 5%, amended to mature on March 31, 2026
$400,000 $400,000 
v3.25.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2025
Equity [Abstract]  
Schedule of Warrants
The following table represents a summary of warrants for the nine months ended September 30, 2025 and the year ended December 31, 2024:
Nine Months Ended
September 30, 2025
Year Ended
December 31, 2024
NumberWeighted
Average
Exercise
Price
NumberWeighted
Average
Exercise
Price
Beginning balance8,744,698$1.40 7,444,698$1.68 
Granted8,666,6671.15 11,631,0350.34 
Exercised(8,509,926)0.83 (10,331,035)0.41 
Expired(3,247,458)1.08 — — 
Ending balance5,653,981$2.05 8,744,698$1.40 
Warrants exercisable 5,653,9818,744,698
Intrinsic value of warrants$53,293 $6,661,661 
Weighted Average Remaining Contractual Life (Years)3.373.86
Schedule of Options
The following represents a summary of options for the Second Amended Plan and additional options granted outside of the Second Amended Plan, for the nine months ended September 30, 2025 and the year ended December 31, 2024:
NumberWeighted
Average
Exercise
Price
Weighted-Average Remaining Contractual Term (in Years)Weighted
Average
Fair Value
Outstanding December 31, 20249,515,000 $2.03 3.89$3.12 
Granted1,855,0001.076.301.05
Exercised(250,000)0.2100.19
Forfeited(687,500)0.802.00
Outstanding September 30, 202510,432,500$1.99 4.08$2.82 
As of September 30, 2025
Vested and exercisable7,601,835$2.09 4.31$2.47 
Schedule of Stock Options, Valuation Assumptions The following assumptions were used for the periods as follows:
Nine Months Ended
September 30, 2025
Year
Ended
December 31, 2024
Expected term7 years7 years
Expected volatility
164.63% – 169.72%
123.05% – 124.33%
Expected dividend yield— — 
Risk-free interest rate
4.14% – 4.51%
3.89% - 4.45%
v3.25.3
Fair Value (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Disclosures [Abstract]  
Summary of derivative liabilities and the contingent earnout fall
The following tables present the Company's financial instruments that are measured at fair value on a recurring basis:
Fair Value Measurements at September 30, 2025
Level 1Level 2Level 3Total
Anticipated Receivable $— $— $160,221 $160,221 
2022 Crom Warrants$— $— $348,000 $348,000 
Fair Value Measurements at December 31, 2024
Level 1Level 2Level 3Total
Anticipated Receivable$— $— $265,739 $265,739 
2022 Crom Warrants$— $— $883,000 $883,000 
Summary of fair value measurements
Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of the 2022 Crom Warrants is estimated using a binomial valuation model. The following assumptions were used for the period as follows:
September 30,
2025
Expected term - warrants
1.51 years
Stock price as of measurement date$1.09 
Volatility (observed)
147.40%
Incremental discount5.0 %
Selected volatility – post haircut
133.1%
Risk-free interest rate
3.61%
v3.25.3
Summary of Significant Accounting Policies (Details)
9 Months Ended
Sep. 30, 2025
USD ($)
segment
contractualArrangementType
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Accounting Policies [Line Items]                
Number of reportable segments | segment 1              
Number of operating segments | segment 1              
Number of contractual arrangement types | contractualArrangementType 3              
Additional paid in capital $ 36,728,812 $ 31,772,502 $ 26,096,732 $ 20,182,026 $ 12,025,064 $ 12,079,321 $ 12,828,113 $ 12,948,689
Obligation to issue common and preferred stock 0     402,708        
Additional Paid-In Capital                
Accounting Policies [Line Items]                
Additional paid in capital 91,958,566 $ 87,391,218 $ 81,366,998 $ 74,256,138 $ 63,329,698 $ 62,074,352 $ 60,946,590 $ 56,926,161
Revision of Prior Period, Error Correction, Adjustment                
Accounting Policies [Line Items]                
Obligation to issue common and preferred stock 274,500              
Revision of Prior Period, Error Correction, Adjustment | Additional Paid-In Capital                
Accounting Policies [Line Items]                
Additional paid in capital $ 274,500              
Maximum                
Accounting Policies [Line Items]                
Contract term 5 years              
v3.25.3
Summary of Significant Accounting Policies - Schedule of Company's Revenue By Contract Type (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Accounting Policies [Line Items]        
Revenue from contract with customer, excluding assessed tax $ 14,619,687 $ 11,608,691 $ 40,308,142 $ 34,466,131
Time and material        
Accounting Policies [Line Items]        
Revenue from contract with customer, excluding assessed tax 4,148,086 6,254,135 13,186,406 18,945,698
Firm fixed price        
Accounting Policies [Line Items]        
Revenue from contract with customer, excluding assessed tax 619,676 810,812 2,045,890 2,323,228
Cost plus fixed fee        
Accounting Policies [Line Items]        
Revenue from contract with customer, excluding assessed tax $ 9,851,925 $ 4,543,744 $ 25,075,846 $ 13,197,205
v3.25.3
Disposition - Additional Information (Detail)
3 Months Ended 9 Months Ended
Sep. 11, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Business Combination [Line Items]          
Gain on sale of subsidiary   $ 0 $ 39,234 $ 0 $ 39,234
Disposal Group, Disposed of by Sale, Not Discontinued Operations | MFSI Divesture          
Business Combination [Line Items]          
Percentage of stock sold 1        
Initial cash payment $ 15,000        
Percentage of future revenue 0.06        
Total payments $ 705,000        
Cash deposits and accounts receivable $ 150,000        
Discount rate 0.085        
Present value of future consideration receivable $ 160,221        
Gain on sale of subsidiary       $ 39,234  
Percentage of revenue   0.05   0.05  
v3.25.3
Fixed Assets - Summary of Fixed Assets (Detail) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Property, Plant and Equipment [Line Items]    
Total fixed assets $ 685,994 $ 541,414
Accumulated depreciation (445,851) (385,303)
Fixed assets, net 240,143 156,111
Equipment and software    
Property, Plant and Equipment [Line Items]    
Total fixed assets 405,988 261,408
Furniture    
Property, Plant and Equipment [Line Items]    
Total fixed assets 43,119 43,119
Automobiles    
Property, Plant and Equipment [Line Items]    
Total fixed assets 43,928 43,928
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total fixed assets $ 192,959 $ 192,959
v3.25.3
Fixed Assets - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 18,753 $ 38,855 $ 57,892 $ 119,942
v3.25.3
Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 16,819,864 $ 16,819,864
Accumulated amortization (11,092,728) (10,026,114)
Intangible assets, net 5,727,136 6,793,750
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 11,613,000 11,613,000
Customer relationships | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 4 years 6 months  
Customer relationships | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 15 years  
Tradename    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 15 years  
Intangible assets, gross $ 783,000 783,000
Trademark    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 533,864 533,864
Trademark | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 10 years  
Trademark | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 15 years  
Backlog    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 3,210,000 3,210,000
Backlog | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 2 years  
Backlog | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 5 years  
Non-compete agreement    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 680,000 $ 680,000
Non-compete agreement | Minimum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 3 years  
Non-compete agreement | Maximum    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, useful life 5 years  
v3.25.3
Intangible Assets and Goodwill - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Line Items]        
Amortization of intangible assets $ 355,537 $ 517,669 $ 1,066,611 $ 1,603,611
Goodwill removed through dispositions     $ 0  
v3.25.3
Intangible Assets and Goodwill - Schedule of Future Amortization of Intangible Assets (Detail) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]    
Remainder of the year ending December 31, 2025 $ 355,537  
Year ending 2026 1,218,182  
Year ending 2027 1,014,558  
Year ending 2028 528,784  
Year ending 2029 441,568  
Year ending 2030 and thereafter 2,168,507  
Intangible assets, net $ 5,727,136 $ 6,793,750
v3.25.3
Intangible Assets and Goodwill - Schedule of Goodwill (Detail)
Sep. 30, 2025
USD ($)
Goodwill [Roll Forward]  
Balance – beginning of period $ 10,676,834
Balance – ending of period 10,676,834
Corvus  
Goodwill [Roll Forward]  
Balance – beginning of period 1,958,741
Balance – ending of period 1,958,741
SSI  
Goodwill [Roll Forward]  
Balance – beginning of period 8,718,093
Balance – ending of period $ 8,718,093
v3.25.3
Notes Payable - Schedule of Notes Payable (Detail) - USD ($)
Sep. 30, 2025
Aug. 04, 2025
Apr. 17, 2025
Dec. 31, 2024
Feb. 22, 2024
Schedule Of Notes Payable [Line Items]          
Notes payable $ 2,000,000     $ 8,000,000  
Note Payable Maturing December 15, 2027 | Notes Payable          
Schedule Of Notes Payable [Line Items]          
Notes payable 2,000,000 $ 2,000,000 $ 2,000,000 6,000,000  
Convertibles Maturing February 13, 2024 | Promissory Note          
Schedule Of Notes Payable [Line Items]          
Notes payable $ 0     2,000,000 $ 2,400,000
Note Payable Maturing August 31, 2026 | Notes Payable          
Schedule Of Notes Payable [Line Items]          
Notes payable       $ 6,000,000  
v3.25.3
Notes Payable - Schedule of Notes Payable - Additional Information (Detail) - USD ($)
24 Months Ended
Aug. 31, 2026
Jan. 02, 2026
Jan. 01, 2026
Sep. 30, 2025
Aug. 04, 2025
Apr. 17, 2025
Feb. 02, 2025
Dec. 31, 2024
Feb. 22, 2024
Debt Instrument [Line Items]                  
Notes payable       $ 2,000,000       $ 8,000,000  
Notes Payable | Note Payable Maturing August 31, 2026                  
Debt Instrument [Line Items]                  
Notes payable               6,000,000  
Interest rate             8.00%   7.50%
Notes Payable | Note Payable Maturing December 15, 2027                  
Debt Instrument [Line Items]                  
Notes payable       2,000,000 $ 2,000,000 $ 2,000,000   6,000,000  
Interest rate           10.00%      
Promissory Note | Convertibles Maturing February 13, 2024                  
Debt Instrument [Line Items]                  
Notes payable       $ 0       $ 2,000,000 $ 2,400,000
Interest rate                 5.00%
Promissory Note | Convertibles Maturing February 13, 2024 | Forecast                  
Debt Instrument [Line Items]                  
Interest rate   12.00% 8.00%            
Debt instrument, periodic payment $ 100,000                
v3.25.3
Notes Payable - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2025
Schedule Of Notes Payable [Line Items]          
Interest expense, debt $ 69,589 $ 181,474 $ 349,507 $ 565,440  
Accrued interest payable current $ 0 $ 0 $ 0 $ 0  
Forecast | Convertible Notes Payable          
Schedule Of Notes Payable [Line Items]          
Promissory note, monthly principal         $ 0
v3.25.3
Note Payable - Related Party - Schedule Of Notes Payable To Related Party (Details) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Schedule of notes payable to related party [Line Items]    
Notes payable $ 2,000,000 $ 8,000,000
SSI | Note payable    
Schedule of notes payable to related party [Line Items]    
Interest rate 5.00% 5.00%
SSI | Related party    
Schedule of notes payable to related party [Line Items]    
Notes payable $ 400,000 $ 400,000
v3.25.3
Note Payable - Related Party - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Aug. 01, 2025
Feb. 16, 2024
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Schedule of notes payable to related party [Line Items]              
Revolving credit facility     $ 0   $ 0   $ 1,999,944
Interest expense         28,658 $ 109,512  
Note payable              
Schedule of notes payable to related party [Line Items]              
Debt instrument, periodic payment $ 50,000 $ 50,000          
Debt instrument, term 8 months 8 months          
Notes payable, current $ 350,000            
Notes payable, noncurrent $ 50,000            
Related party              
Schedule of notes payable to related party [Line Items]              
Interest expense     $ 5,041 $ 5,027 $ 14,959 $ 14,973  
v3.25.3
Revolving Credit Facility - Additional Information (Detail) - USD ($)
9 Months Ended
Feb. 13, 2025
Feb. 22, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Aug. 15, 2024
Apr. 04, 2022
Line of Credit Facility [Line Items]              
Revolving credit facility     $ 0   $ 1,999,944    
Repaid amount $ 1,999,944            
Interest expense     28,658 $ 109,512      
Revolving Credit Facility              
Line of Credit Facility [Line Items]              
Long-term line of credit     $ 0        
Amount rolled over   $ 625,000          
Borrowing capacity   4,000,000       $ 2,000,000  
Collateral           $ 250,000  
Revolving Credit Facility | Live Oak Bank              
Line of Credit Facility [Line Items]              
Long-term line of credit             $ 950,000
Proceeds from lines of credit   $ 904,793          
v3.25.3
Due To Seller - Additional Information (Detail)
Feb. 15, 2024
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Business Combination [Line Items]      
Settlement $ 720,000    
Settlement, initial payment 180,000    
Settlement, periodic payment amount $ 20,000    
Settlement, interest percent 0.05    
Settlement, term 27 months    
Due to seller   $ 160,000 $ 240,000
SSI      
Business Combination [Line Items]      
Due to seller   $ 160,000  
v3.25.3
Stockholders' Equity - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 21, 2025
Jun. 13, 2025
Jun. 11, 2025
Mar. 19, 2025
Feb. 12, 2025
Jan. 10, 2025
Jan. 08, 2025
Jan. 03, 2025
Jan. 25, 2024
Feb. 28, 2025
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2024
Sep. 17, 2025
Mar. 11, 2025
Dec. 31, 2023
Nov. 09, 2023
Nov. 09, 2021
Class of Stock [Line Items]                                              
Preferred stock, shares authorized (in shares)                     50,000,000       50,000,000 50,000,000   50,000,000          
Preferred stock dividend                             $ 80,623   $ 89,458            
Common stock, shares authorized (in shares)                     3,000,000,000       3,000,000,000 3,000,000,000   3,000,000,000          
Common stock par or stated value per share (in usd per share)                     $ 0.0001       $ 0.0001 $ 0.0001   $ 0.0001          
Common stock, shares, issued (in shares)                     94,612,750       94,612,750 77,076,129   77,076,129          
Common stock, shares outstanding (in shares)                     94,612,750       94,612,750 77,076,129   77,076,129          
Sale of stock, price per share (in usd per share)                 $ 0.32                            
Shares issued in exercise of stock options (in shares)                             250,000                
Authorized debt and equity securities           $ 100,000,000                                  
Stock Incentive Plan                                              
Class of Stock [Line Items]                                              
Common stock, shares authorized (in shares)                                     9,000,000        
Equity instruments other than options, grants in period (in shares)                             5,887,500                
Number of shares authorized (in shares)                                       9,000,000   6,000,000 2,500,000
2025 Employee Stock Purchase Plan                                              
Class of Stock [Line Items]                                              
Common stock, shares authorized (in shares)                                     3,000,000        
Warrant                                              
Class of Stock [Line Items]                                              
Proceeds from issuance of common stock         $ 1         $ 700,000                          
Exercised (in usd per share)                             $ 0.83     $ 0.41          
Shares issued in exercise of stock options (in shares)                   2,000,000         8,509,926 6,437,501   10,331,035          
Exercised warrants (in shares)         1,080,717                                    
Options, grants in period, weighted average exercise price (in usd pre share)                             $ 1.15     $ 0.34          
Remaining warrants (in shares)                     5,653,981       5,653,981 8,744,698   8,744,698     7,444,698    
Warrant | March 2025 Public Offering                                              
Class of Stock [Line Items]                                              
Exercise price of warrants or rights (in usd per share)                     $ 1.08       $ 1.08                
Exercised warrants (in shares)                             1,755,543                
Proceeds from warrant exercises                             $ 1,900,000                
Warrant expiration period                             60 days                
Warrants expired in period (in shares)                             2,744,457                
Warrant | June 2025 Public Offering                                              
Class of Stock [Line Items]                                              
Exercise price of warrants or rights (in usd per share)                     $ 1.22       $ 1.22                
Exercised warrants (in shares)                             3,673,666                
Proceeds from warrant exercises                             $ 4,480,000                
Warrant expiration period                             60 days                
Warrants expired in period (in shares)                             493,001                
Options                                              
Class of Stock [Line Items]                                              
Exercised (in usd per share)                             $ 0.210                
Options, grants in period, weighted average exercise price (in usd pre share)                             $ 1.07                
Stock issued during period, shares, new issues (in shares) 125,000             110,028                              
Remaining warrants (in shares)                     10,432,500       10,432,500 9,515,000   9,515,000          
Restricted Stock                                              
Class of Stock [Line Items]                                              
Equity instruments other than options, grants in period (in shares)     0                       515,464                
Vesting period                             1 year                
Non-cash stock based compensation                             $ 146,768                
Cash payment     $ 146,700                                        
Service-Based Stock Option                                              
Class of Stock [Line Items]                                              
Non-cash stock based compensation                             $ 2,103,344                
Warrant                                              
Class of Stock [Line Items]                                              
Exercise price of warrants or rights (in usd per share)                     $ 0.35       $ 0.35 $ 0.35   $ 0.35          
Warrants (in shares)                     8,437,501       8,437,501                
Exercisable term                             5 years                
Common Stock                                              
Class of Stock [Line Items]                                              
Shares issued in exercise of stock options (in shares)                     125,000 110,028                      
Stock issued during period, shares, new issues (in shares)                         3,080,014 5,357,487 17,536,621                
Common Stock | Warrant                                              
Class of Stock [Line Items]                                              
Warrants (in shares)         1,080,717         2,000,000                          
Convertible Notes Payable                                              
Class of Stock [Line Items]                                              
Exercise price of warrants or rights (in usd per share)                 0.319                            
Pre-Funded Warrants                                              
Class of Stock [Line Items]                                              
Exercise price of warrants or rights (in usd per share)                 $ 0.001                            
Convertible Notes Payable                                              
Class of Stock [Line Items]                                              
Number of warrants issued                 3,193,534                            
SPA Agreement                                              
Class of Stock [Line Items]                                              
Number of shares issued in transaction (in shares)                 5,243,967                            
Proceeds from issuance of common stock                 $ 2,700,000                            
Public Offering | March 2025 Public Offering                                              
Class of Stock [Line Items]                                              
Number of shares issued in transaction (in shares)       4,500,000                                      
Sale of stock, price per share (in usd per share)       $ 1.00                                      
Proceeds from issuance of common stock       $ 4,500,000                                      
Public Offering | June 2025 Public Offering                                              
Class of Stock [Line Items]                                              
Number of shares issued in transaction (in shares)   4,166,667                                          
Sale of stock, price per share (in usd per share)   $ 1.20                                          
Proceeds from issuance of common stock   $ 5,000,000                                          
Series A Preferred                                              
Class of Stock [Line Items]                                              
Preferred stock, shares authorized (in shares)                     10,000,000       10,000,000 10,000,000   10,000,000          
Preferred stock par or stated value per share (in usd per share)                     $ 0.0001       $ 0.0001 $ 0.0001   $ 0.0001          
Preferred stock, shares outstanding (in shares)                     5,875,000       5,875,000 5,875,000   5,875,000          
Preferred stock, shares issued (in shares)                     5,875,000       5,875,000 5,875,000   5,875,000          
Conversion of stock, shares converted (in shares)                             587,500                
Preferred stock dividend                             $ 54,808   54,808            
Series B Preferred                                              
Class of Stock [Line Items]                                              
Preferred stock, shares authorized (in shares)                     10,000,000       10,000,000                
Preferred stock par or stated value per share (in usd per share)                     $ 0.0001       $ 0.0001                
Preferred stock, shares outstanding (in shares)                     0       0 0   0          
Preferred stock, shares issued (in shares)                     0       0 0   0          
Series C Preferred                                              
Class of Stock [Line Items]                                              
Preferred stock, shares authorized (in shares)                     10,000,000       10,000,000 10,000,000   10,000,000          
Preferred stock par or stated value per share (in usd per share)                     $ 0.0001       $ 0.0001 $ 0.0001   $ 0.0001          
Preferred stock, shares outstanding (in shares)                     570,000       570,000 770,000   770,000          
Preferred stock, shares issued (in shares)                     570,000       570,000 770,000   770,000          
Conversion of stock, shares converted (in shares)                             356,250                
Preferred stock dividend                             $ 25,815   $ 34,650            
Shares issued on conversion (in shares)             0.625 0.625                              
Series C Preferred | Preferred Stock                                              
Class of Stock [Line Items]                                              
Shares converted (in shares)             200,000 200,000                              
Series C Preferred | Common Stock                                              
Class of Stock [Line Items]                                              
Conversion of stock, shares issued (in shares)             125,000 125,000                              
v3.25.3
Stockholders' Equity - Schedule of warrants (Detail) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2025
Sep. 30, 2025
Dec. 31, 2024
Dec. 31, 2024
Number        
Exercised (in shares)   (250,000)    
Weighted Average Remaining Contractual Life (Years)   4 years 29 days    
Warrant        
Number        
Beginning balance (in shares)   8,744,698   7,444,698
Granted (in shares)   8,666,667   11,631,035
Exercised (in shares) (2,000,000) (8,509,926) (6,437,501) (10,331,035)
Expired (in shares)   (3,247,458)   0
Ending balance (in shares)   5,653,981 8,744,698 8,744,698
Warrants exercisable (in shares)   5,653,981 8,744,698 8,744,698
Intrinsic value of warrants   $ 53,293 $ 6,661,661 $ 6,661,661
Weighted Average Remaining Contractual Life (Years)   3 years 4 months 13 days   3 years 10 months 9 days
Weighted Average Exercise Price        
Beginning balance (in usd per share)   $ 1.40   $ 1.68
Granted (in usd per share)   1.15   0.34
Exercised (in usd per share)   0.83   0.41
Expired (in usd per share)   1.08   0
Ending balance (in usd per share)   $ 2.05 $ 1.40 $ 1.40
v3.25.3
Stockholders' Equity - Schedule of options (Detail) - $ / shares
3 Months Ended 9 Months Ended
Mar. 31, 2025
Sep. 30, 2025
Number    
Options exercised in period (in shares)   (250,000)
Forfeited (in shares)   (687,500)
Weighted-Average Remaining Contractual Term (in Years)    
Weighted average remaining contractual term (in years)   4 years 29 days
Weighted average remaining contractual term, granted (in years)   6 years 3 months 18 days
Weighted average remaining contractual term, exercised (in years)   0 years
Weighted Average Fair Value    
Weighted average fair value, granted (in usd per share)   $ 1.05
Weighted average fair value, exercised (in usd per share)   0.19
Weighted average fair value, forfeited (in usd per share)   $ 2.00
Options    
Number    
Beginning balance (in shares) 9,515,000 9,515,000
Granted (in shares)   1,855,000
Ending balance (in shares)   10,432,500
Vested and exercisable (in shares) 7,601,835  
Weighted Average Exercise Price    
Beginning balance (in usd per share) $ 2.03 $ 2.03
Granted (in usd per share)   1.07
Exercised (in usd per share)   0.210
Forfeited (in usd per share)   0.80
Ending balance (in usd per share)   1.99
Weighted average exercise price, vested and expected to vest (in usd per share) $ 2.09  
Weighted-Average Remaining Contractual Term (in Years)    
Weighted average remaining contractual term (in years) 3 years 10 months 20 days  
Weighted average remaining contractual term, vested and exercisable (in years) $ 4.31  
Weighted Average Fair Value    
Beginning weighted average fair value (in usd per share) 3.12 3.12
Ending weighted average fair value (in usd per share)   $ 2.82
Weighted average fair value, vested and exercisable (in usd per share) $ 2.47  
v3.25.3
Stockholders' Equity - Schedule of Stock Options, Valuation Assumptions (Detail)
3 Months Ended 9 Months Ended
Mar. 31, 2025
Sep. 30, 2025
Equity [Abstract]    
Expected term 7 years 7 years
Expected volatility minimum 123.05% 164.63%
Expected volatility maximum 124.33% 169.72%
Expected dividend yield 0.00% 0.00%
Risk-free interest rate minimum 3.89% 4.14%
Risk-free interest rate maximum 4.45% 4.51%
v3.25.3
Fair Value - Summary of Derivative Liabilities and the Contingent Earn out Fall (Detail) - USD ($)
Sep. 30, 2025
Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Anticipated Receivable $ 160,221 $ 265,739
2022 Crom Warrants $ 348,000 $ 883,000
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative liability Derivative liability
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Anticipated Receivable $ 0 $ 0
2022 Crom Warrants 0 0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Anticipated Receivable 0 0
2022 Crom Warrants 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Anticipated Receivable 160,221 265,739
2022 Crom Warrants $ 348,000 $ 883,000
v3.25.3
Fair Value - Summary of Fair Value Measurements (Detail)
Sep. 30, 2025
USD ($)
Expected term - warrants  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, term 1 year 6 months 3 days
Stock price as of measurement date  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, measurement input 1.09
Volatility (observed)  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, measurement input 1.4740
Incremental discount  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, measurement input 0.050
Selected volatility – post haircut  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, measurement input 1.331
Risk-free interest rate  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Derivative liability, measurement input 0.0361
v3.25.3
Concentrations - Additional Information (Details)
6 Months Ended 9 Months Ended
Jun. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Three Customers | Revenue, Product and Service Benchmark | Revenue from Rights Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage   72.00% 52.00%
Three Customers | Accounts Receivable | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage   72.00%  
Four Customers | Accounts Receivable | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 65.00%    
v3.25.3
Income Taxes - Additional Information (Detail)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Income Tax Disclosure [Abstract]        
Effective income tax rate, percent (20.40%) (16.75%) 10.80% 0.00%
v3.25.3
Subsequent Events - Additional Information (Detail) - USD ($)
1 Months Ended 9 Months Ended
Nov. 06, 2025
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Subsequent Event [Line Items]        
Repayment of amounts due to seller   $ 180,000 $ 670,000  
Amount due to seller, balance   $ 160,000   $ 240,000
Subsequent Event        
Subsequent Event [Line Items]        
Repayment of amounts due to seller $ 140,000      
Amount due to seller, balance $ 0